Washington, D.C. 20549
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
EXHIBIT 99.1
Anika Reports First Quarter 2026 Financial Results
Grew total company revenue 13%, driven by Commercial Channel strength and favorable OEM Channel order timing
Delivered 64% gross margin, +8 points year over year, driven by improved operational execution
Operational transformation generating early wins, delivering $4 million of adjusted EBITDA
BEDFORD, Mass., April 29, 2026 (GLOBE NEWSWIRE) -- Anika Therapeutics, Inc. (Nasdaq: ANIK), a global leader in the osteoarthritis (“OA”) pain management and regenerative solutions spaces focused on early‑intervention orthopedics, today announced financial results for the first quarter of 2026.
Total revenue for the first quarter of 2026 was $29.6 million, compared to $26.2 million in the prior-year period, representing growth of 13%. Growth was driven by strength across both channels, with OEM Channel revenue of $17.0 million, up 14%, and Commercial Channel revenue of $12.6 million, up 12% year-over-year.
Gross profit for the first quarter was $19.0 million, compared to $14.7 million in the prior-year period. Gross margin improved to 64.2%, compared to 56.1% in the first quarter of 2025, driven by operational execution, ongoing margin improvement initiatives and favorable product mix.
Total operating expenses were $24.5 million, compared to $19.0 million in the prior-year period, primarily reflecting $4.9 million of one-time severance costs. Remaining increases were largely related to investments in operations and research and development expenses to support ongoing programs.
Adjusted EBITDA for the first quarter of 2026 was $4.3 million, compared to $0.1 million in the first quarter of 2025, reflecting strong gross margin expansion and disciplined operational execution.
“Our strategic transformation and organizational realignment is yielding results and driving improved profitability and efficiencies throughout the organization,” said Steve Griffin, President and Chief Executive Officer of Anika Therapeutics. “We delivered a strong start to 2026, highlighted by double-digit revenue growth and gross margin expansion, which improved adjusted EBITDA. These results were led by strong growth in our Commercial Channel with Regenerative Solutions increasing 20% year over year, driven by 35% US procedure growth from Integrity, which generated $1.8 million in revenue during the quarter. In addition, OEM Channel performance reflected a combination of favorable order timing, lower 2025 sales volume, and solid execution by our teams to start 2026, contributing to a 14% revenue increase year over year.
Our margin performance in the first quarter demonstrates the leverage in our business model as volume scales and operational initiatives take hold, including the deployment of lean manufacturing principles that are enabling our teams to increase throughput and drive improved performance. These initiatives are designed to support our operations as we advance our portfolio through FDA review and position the company to scale production in anticipation of future growth. At the same time, we continue to make targeted investments across our regenerative pipeline and commercial business to position Anika for sustainable, profitable long-term growth.”
First Quarter 2026 Business Highlights and Current Business Updates
- International OA Pain Management grew 9% in the first quarter reaching $8.9 million, led by continued regional expansion and improved market share.
- Integrity continued to demonstrate strong momentum, with U.S. sales execution driving a 35% increase in procedures year over year and generating $1.8 million in revenue. Growth was driven by sustained surgeon adoption in the U.S., the successful launch of larger Integrity sizes that expand addressable tendon applications, and increasing international penetration.
- Hyalofast PMA engagement with FDA continues to progress and review timeline remains in line with the previously provided timeline.
- Cingal bioequivalence study enrollment remains on track in preparation for an FDA NDA submission including necessary CMC work to support HA as a drug.
- OEM channel year over year growth driven by order timing of non-orthopedic and US OA Pain Management products including continued strong Monovisc demand
- Targeted operational investments improving productivity, discipline, and scalability
First Quarter 2026 Continuing Operations Financial Summary
- Revenue $29.6 million, up 13% year over year
- Commercial Channel revenue $12.6 million, up 12%
- OEM Channel revenue $17.0 million, up 14%
- Gross margin 64.2%
- Operating expenses $24.5 million, including $4.9 million of one-time severance expenses
- GAAP loss from continuing operations $5.1 million, ($0.37) per diluted share
- Adjusted net income from continuing operations1 $3.8 million, $0.27 per diluted share
- Adjusted EBITDA1 $4.3 million
- Cash and cash equivalents $41.0 million as of March 31, 2026
1 See description of non-GAAP financial information contained in this release.
Fiscal 2026 Guidance
Anika is maintaining the previously provided 2026 guidance:
- Total Company Revenue between $114 and $122.5 million, up 1% to 9% year over year
- Commercial Channel, $53 to $58 million, representing growth of 10% to 20% year over year
- OEM Channel, $61 to $64.5 million, flat to modestly lower year over year
- Adjusted EBITDA as a percent of revenue between 5% and 10%, reflecting higher revenues and reduced expenses offset by modestly lower U.S. pricing dynamics.
Company Completes $15 Million 10b5-1 Share Repurchase
The company completed its previously announced $15 million 10b5-1 share repurchase on April 10, 2026, with an average price of $10.76 per share.
Corporate Governance Update
As disclosed in the Company’s definitive proxy statement filed on April 28, 2026, Dr. Glenn Larsen and Bill Jellison have informed the Board of their intention to step down as directors as of the 2026 Annual Meeting as part of the Company’s continued transformation, with neither resignation related to any disagreement with the Company, management, or the Board.
The Company is grateful to Dr. Larsen and Mr. Jellison for their dedication and valuable contributions to Anika.
Conference Call and Webcast Information
Anika’s management will hold a conference call and webcast to discuss its financial results and business highlights today, Wednesday, April 29, 2026, at 8:30 am ET. The conference call can be accessed by dialing 1-800-717-1738 (toll-free domestic) or 1-646-307-1865 (international) and providing the conference ID number 82141. A live audio webcast will be available in the Investor Relations section of Anika’s website, www.anika.com. A slide presentation with highlights from the conference call will be available in the Investor Relations section of the Anika website. A replay of the webcast will be available on Anika’s website approximately two hours after the completion of the event.
About Anika
Anika Therapeutics, Inc. (NASDAQ: ANIK), is the global leader in the design, development, manufacturing, and commercialization of hyaluronic acid innovations. In partnership with clinicians, our sole focus is dedicated to delivering and advancing osteoarthritis pain management and orthopedic regenerative solutions. At our core is a passion to deliver a differentiated portfolio that improves patient outcomes around the world. Anika’s global operations are headquartered outside of Boston, Massachusetts. For more information about Anika, please visit www.anika.com.
ANIKA, ANIKA THERAPEUTICS, CINGAL, HYALOFAST, INTEGRITY, MONOVISC, and the Anika logo are trademarks of Anika Therapeutics, Inc. or its subsidiaries or are licensed to Anika Therapeutics, Inc. for its use.
Non-GAAP Financial Information1
Non-GAAP financial measures should be considered supplemental to, and not a substitute for, the Company’s reported financial results prepared in accordance with GAAP. Furthermore, the Company’s definition of non-GAAP measures may differ from similarly titled measures used by others. Because non-GAAP financial measures exclude the effect of items that will increase or decrease the Company’s reported results of operations, Anika strongly encourages investors to review the Company’s consolidated financial statements and publicly filed reports in their entirety. The Company presents these non-GAAP financial measures because it uses them as supplemental measures in internally assessing the Company’s operating performance, and, in the case of Adjusted EBITDA, it is set as a key performance metric to determine executive compensation. The Company also recognizes that these non-GAAP measures are commonly used in determining business performance more broadly and believes that they are helpful to investors, securities analysts, and other interested parties as a measure of comparative operating performance from period to period.
Adjusted EBITDA
Adjusted EBITDA is defined by the Company as GAAP net income (loss) from continuing operations excluding depreciation and amortization, interest and other income (expense), income taxes, stock-based compensation expense, and shareholder activism costs.
Adjusted Net Income (Loss) from Continuing Operations and Adjusted EPS from Continuing Operations
Adjusted net income (loss) is defined by the Company as GAAP net income from continuing operations, on a tax effected basis, excluding stock-based compensation. Adjusted diluted EPS from continuing operations is defined by the Company as GAAP diluted EPS from continuing operations excluding stock-based compensation.
A reconciliation of adjusted EBITDA to adjusted net income (loss) from continuing operations to net income (loss) from continuing operations and adjusted diluted EPS from continuing operations to diluted EPS from continuing operations, the most directly comparable financial measures calculated and presented in accordance with GAAP, is shown in the tables at the end of this release.
Forward-Looking Statements
This press release may contain forward-looking statements, within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, concerning the Company's expectations, anticipations, intentions, beliefs or strategies regarding the future which are not statements of historical fact, including statements in the section titled “Fiscal 2026 Guidance” regarding 2026 revenue and adjusted EBITDA. These statements are based upon the current beliefs and expectations of the Company's management and are subject to significant risks, uncertainties, and other factors. The Company's actual results could differ materially from any anticipated future results, performance, or achievements described in the forward-looking statements as a result of a number of factors including, but not limited to, (i) the Company's ability to successfully commence and/or complete clinical trials of its products on a timely basis or at all; (ii) the Company's ability to obtain pre-clinical or clinical data to support, or to timely file domestic and international pre-market approval applications, 510(k) applications, or new drug applications, including the PMA for Hyalofast and the NDA for Cingal; (iii) that the FDA or other regulatory bodies may not approve or clear the Company’s applications, including the Hyalofast PMA because of the failure to achieve the pre-defined primary endpoints or because the FDA may determine that achievement of secondary endpoints and/or post hoc data analyses are not sufficient to support approval; (iv) that such approvals or clearances will not be obtained in a timely manner or without the need for additional clinical trials, other testing or regulatory submissions, as applicable; (v) the Company's research and product development efforts and their relative success, including whether we have any meaningful sales of any new products resulting from such efforts; (vi) the cost effectiveness and efficiency of the Company's clinical studies, manufacturing operations, and production planning; (vii) the strength of the economies in which the Company operates or will be operating, as well as the political stability of any of those geographic areas; (viii) future determinations by the Company to allocate resources to products and in directions not presently contemplated; (ix) the Company's ability to successfully commercialize its products, in the U.S. and abroad; (x) the Company's ability to provide an adequate and timely supply of its products to its customers; and (xi) the Company's ability to achieve its growth targets. Additional factors and risks are described in the Company's periodic reports filed with the Securities and Exchange Commission, and they are available on the SEC's website at www.sec.gov. Forward-looking statements are made based on information available to the Company on the date of this press release, and the Company assumes no obligation to update the information contained in this press release.
For Investor Inquiries:
Anika Therapeutics, Inc.
Matt Hall, 781-457-9554
Executive Director, Corporate Development and Investor Relations
investorrelations@anika.com
| Anika Therapeutics, Inc. and Subsidiaries |
| Consolidated Statements of Operations |
| (in thousands, except per share data) |
| (unaudited) |
| | | | | | | | | | |
| | | For the Three Months Ended March 31, | | For the Three Months Ended March 31, |
| | | | 2026 | | | | 2025 | | | | 2026 | | | | 2025 | | |
| Revenue | | $ | 29,612 | | | $ | 26,168 | | | $ | 29,612 | | | $ | 26,168 | | |
| Cost of Revenue | | | 10,615 | | | | 11,487 | | | | 10,615 | | | | 11,487 | | |
| Gross Profit | | | 18,997 | | | | 14,681 | | | | 18,997 | | | | 14,681 | | |
| | | | | | | | | | |
| Operating expenses: | | | | | | | | | |
| Research and development | | | 6,713 | | | | 6,059 | | | | 6,713 | | | | 6,059 | | |
| Selling, general and administrative | | | 17,772 | | | | 12,906 | | | | 17,772 | | | | 12,906 | | |
| Total operating expenses | | | 24,485 | | | | 18,965 | | | | 24,485 | | | | 18,965 | | |
| Loss from operations | | | (5,488 | ) | | | (4,284 | ) | | | (5,488 | ) | | | (4,284 | ) | |
| Interest and other income (expense), net | | | 667 | | | | 415 | | | | 667 | | | | 415 | | |
| Loss before income taxes | | | (4,821 | ) | | | (3,869 | ) | | | (4,821 | ) | | | (3,869 | ) | |
| Provision for income taxes | | | 235 | | | | 89 | | | | 235 | | | | 89 | | |
| Loss from continuing operations | | | (5,056 | ) | | | (3,958 | ) | | | (5,056 | ) | | | (3,958 | ) | |
| Loss from discontinued operations, net of tax | | | - | | | | (915 | ) | | | - | | | | (915 | ) | |
| Net loss | | $ | (5,056 | ) | | $ | (4,873 | ) | | $ | (5,056 | ) | | $ | (4,873 | ) | |
| | | | | | | | | | |
| Net loss per share: | | | | | | | | | |
| Basic | | | | | | | | | |
| Continuing Operations | | $ | (0.37 | ) | | $ | (0.28 | ) | | $ | (0.37 | ) | | $ | (0.28 | ) | |
| Discontinued Operations | | $ | - | | | $ | (0.06 | ) | | $ | - | | | $ | (0.06 | ) | |
| | | $ | (0.37 | ) | | $ | (0.34 | ) | | $ | (0.37 | ) | | $ | (0.34 | ) | |
| | | | | | | | | | |
| Diluted | | | | | | | | | |
| Continuing Operations | | $ | (0.37 | ) | | $ | (0.28 | ) | | $ | (0.37 | ) | | $ | (0.28 | ) | |
| Discontinued Operations | | $ | - | | | $ | (0.06 | ) | | $ | - | | | $ | (0.06 | ) | |
| | | $ | (0.37 | ) | | $ | (0.34 | ) | | $ | (0.37 | ) | | $ | (0.34 | ) | |
| | | | | | | | | | |
| Weighted average common shares outstanding: | | | | | | | | | |
| Basic | | | 13,531 | | | | 14,297 | | | | 13,531 | | | | 14,297 | | |
| Diluted | | | 13,531 | | | | 14,297 | | | | 13,531 | | | | 14,297 | | |
| | | | | | | | | | |
| Anika Therapeutics, Inc. and Subsidiaries | |
| Consolidated Balance Sheets | |
| (in thousands, except per share data) | |
| (unaudited) | |
| | | | | |
| | March 31, | | December 31, | |
| ASSETS | | 2026 | | | | 2025 | | |
| Current assets: | | | | |
| Cash and cash equivalents | $ | 41,020 | | | $ | 57,481 | | |
| Accounts receivable, net | | 25,768 | | | | 23,690 | | |
| Inventories, net | | 22,838 | | | | 18,787 | | |
| Prepaid expenses and other current assets | | 3,935 | | | | 3,400 | | |
| Total current assets | | 93,561 | | | | 103,358 | | |
| Property and equipment, net | | 39,722 | | | | 40,324 | | |
| Right-of-use assets | | 25,430 | | | | 25,939 | | |
| Other long-term assets | | 4,303 | | | | 4,034 | | |
| Notes receivable | | 5,679 | | | | 5,636 | | |
| Deferred tax assets | | 1,150 | | | | 1,275 | | |
| Intangible assets, net | | 1,650 | | | | 1,650 | | |
| Goodwill | | 7,892 | | | | 8,054 | | |
| Total assets | $ | 179,387 | | | $ | 190,270 | | |
| | | | | |
| LIABILITIES AND STOCKHOLDERS’ EQUITY | | | | |
| Current liabilities: | | | | |
| Accounts payable | $ | 6,339 | | | $ | 6,041 | | |
| Accrued expenses and other current liabilities | | 14,627 | | | | 15,867 | | |
| Total current liabilities | | 20,966 | | | | 21,908 | | |
| Other long-term liabilities | | 726 | | | | 701 | | |
| Lease liabilities | | 23,794 | | | | 24,196 | | |
| | | | | |
| Stockholders’ equity: | | | | |
| Common stock, $0.01 par value | | 133 | | | | 139 | | |
| Additional paid-in-capital | | 83,347 | | | | 87,498 | | |
| Accumulated other comprehensive loss | | (5,310 | ) | | | (4,959 | ) | |
| Retained earnings | | 55,731 | | | | 60,787 | | |
| Total stockholders’ equity | | 133,901 | | | | 143,465 | | |
| Total liabilities and stockholders’ equity | $ | 179,387 | | | $ | 190,270 | | |
| | | | | |
| Anika Therapeutics, Inc. and Subsidiaries | |
| Consolidated Statements of Cash Flows | |
| (in thousands) | |
| (unaudited) | |
| | For the Three Months Ended March 31, | |
| | | 2026 | | | | 2025 | | |
| Cash flows from operating activities: | | | | |
| Net loss | $ | (5,056 | ) | | $ | (4,873 | ) | |
| Adjustments to reconcile net income to net cash provided by operating activities: | | | | |
| Depreciation | | 1,407 | | | | 1,383 | | |
| Amortization of acquisition related intangible assets | | - | | | | 209 | | |
| Non-cash operating lease cost | | 464 | | | | 577 | | |
| Stock-based compensation expense | | 6,641 | | | | 2,863 | | |
| Deferred income taxes | | 108 | | | | 18 | | |
| Provision for doubtful accounts | | (24 | ) | | | (346 | ) | |
| Provision for inventory | | 1,032 | | | | 832 | | |
| Interest income on notes receivable | | (179 | ) | | | (224 | ) | |
| Gain on sale of assets | | (52 | ) | | | (300 | ) | |
| Changes in operating assets and liabilities: | | | | |
| Accounts receivable | | (2,180 | ) | | | 3,034 | | |
| Inventories | | (5,407 | ) | | | 523 | | |
| Prepaid expenses, other current and long-term assets | | (1,728 | ) | | | (203 | ) | |
| Accounts payable | | 745 | | | | 47 | | |
| Operating lease liabilities | | (468 | ) | | | (569 | ) | |
| Accrued expenses, other current and long-term liabilities | | (1,339 | ) | | | (3,088 | ) | |
| Income taxes | | 1,190 | | | | (13 | ) | |
| Net cash provided by operating activities | | (4,846 | ) | | | (130 | ) | |
| | | | | |
| Cash flows from investing activities: | | | | |
| Purchases of property and equipment | | (1,431 | ) | | | (2,824 | ) | |
| Proceeds from sale of Parcus | | - | | | | 4,496 | | |
| Note receivable | | 192 | | | | - | | |
| Net cash used in investing activities | | (1,239 | ) | | | 1,672 | | |
| | | | | |
| Cash flows from financing activities: | | | | |
| Repurchases of common stock | | (8,690 | ) | | | (3,971 | ) | |
| Cash paid for tax withheld on vested restricted stock awards | | (1,657 | ) | | | (1,467 | ) | |
| Net cash used in financing activities | | (10,347 | ) | | | (5,438 | ) | |
| | | | | |
| Exchange rate impact on cash | | (29 | ) | | | 108 | | |
| | | | | |
| Increase (decrease) in cash and cash equivalents | | (16,461 | ) | | | (3,788 | ) | |
| Cash and cash equivalents at beginning of period | | 57,481 | | | | 57,159 | | |
| Cash and cash equivalents at end of period | $ | 41,020 | | | $ | 53,371 | | |
| | | | | |
Anika Therapeutics, Inc. and Subsidiaries
|
Reconciliation of GAAP Income (Loss) from Continued Operations to Adjusted EBITDA
|
(in thousands)
|
(unaudited)
|
| | | | | | | |
| | For the Three Months Ended March 31, | For the Years Ended March 31, |
| | | 2026 | | | | 2025 | | | 2026 | | | | 2025 | |
| Loss from continuing operations | $ | (5,056 | ) | | $ | (3,958 | ) | $ | (5,056 | ) | | $ | (3,958 | ) |
| Interest and other (income) expense, net | | (667 | ) | | | (415 | ) | | (667 | ) | | | (415 | ) |
| Provision for income taxes | | 235 | | | | 89 | | | 235 | | | | 89 | |
| Depreciation and amortization | | 1,407 | | | | 1,416 | | | 1,407 | | | | 1,416 | |
| Stock-based compensation | | 6,641 | | | | 2,995 | | | 6,641 | | | | 2,995 | |
| Non-recurring professional fees | | 169 | | | | - | | | 169 | | | | - | |
| Severance costs | | 1,587 | | | | - | | | 1,587 | | | | - | |
| Adjusted EBITDA | $ | 4,316 | | | $ | 127 | | $ | 4,316 | | | $ | 127 | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
Anika Therapeutics, Inc. and Subsidiaries
|
Reconciliation of GAAP Net Income from Continuing Operations to Adjusted Net Income from Continuing Operations
|
(in thousands)
|
(unaudited)
|
| | | | | | | |
| | For the Three Months Ended March 31, | For the Years Ended March 31, |
| | | 2026 | | | | 2025 | | | 2026 | | | | 2025 | |
| Loss from continuing operations | $ | (5,056 | ) | | $ | (3,958 | ) | $ | (5,056 | ) | | $ | (3,958 | ) |
| Product rationalization, tax effected | | - | | | | - | | | - | | | | - | |
| Arbitration settlement, tax effected | | - | | | | - | | | - | | | | - | |
| Stock-based compensation, tax effected | | 6,965 | | | | 3,063 | | | 6,965 | | | | 3,063 | |
| Non-recurring professional fees, tax effected | | 177 | | | | - | | | 177 | | | | - | |
| Severance costs, tax effected | | 1,664 | | | | - | | | 1,664 | | | | - | |
| Adjusted net income (loss) from continuing operations | $ | 3,750 | | | $ | (895 | ) | | 3,750 | | | $ | (895 | ) |
| | | | | | | |
Anika Therapeutics, Inc. and Subsidiaries
|
Reconciliation of GAAP Diluted Earnings from Continuing Operations Per Share to Adjusted Diluted Earnings from Continuing Operations Per Share
|
(in thousands, except per share data)
|
(unaudited)
|
| | | | | | | |
| | For the Three Months Ended March 31, | For the Years Ended March 31, |
| | | 2026 | | | | 2025 | | | 2026 | | | | 2025 | |
| Diluted loss from continuing operations per share | $ | (0.37 | ) | | $ | (0.28 | ) | $ | (0.37 | ) | | $ | (0.28 | ) |
| Stock-based compensation, tax effected | | 0.51 | | | | 0.22 | | $ | 0.51 | | | | 0.22 | |
| Non-recurring professional fees, tax effected | | 0.01 | | | | $ | 0.01 | | | | - | |
| Severance costs, tax effected | | 0.12 | | | | - | | | 0.12 | | | | - | |
| Costs of shareholder activism, tax effected | | - | | | | - | | | - | | | | - | |
| Adjusted diluted net income (loss) from continuing operations per share | $ | 0.27 | | | $ | (0.06 | ) | $ | 0.27 | | | $ | (0.06 | ) |
| | | | | | | |
| Anika Therapeutics, Inc. and Subsidiaries | |
| Revenue by Product Family | |
| (in thousands, except percentages) | |
| (unaudited) | |
| | | | | | | | | | | | | | | | | |
| | For the Three Months Ended March 31, | | For the Three Months Ended March 31, | |
| | | 2026 | | | 2025 | | $ change | | % change | | | 2026 | | | 2025 | | $ change | | % change | |
| OEM Channel | $ | 17,035 | | $ | 14,909 | | $ | 2,126 | | 14 | % | | $ | 17,035 | | $ | 14,909 | | $ | 2,126 | | 14 | % | |
| Commercial Channel | | 12,577 | | | 11,259 | | | 1,318 | | 12 | % | | | 12,577 | | | 11,259 | | | 1,318 | | 12 | % | |
| | $ | 29,612 | | $ | 26,168 | | $ | 3,444 | | 13 | % | | $ | 29,612 | | $ | 26,168 | | $ | 3,444 | | 13 | % | |
| | | | | | | | | | | | | | | | | |
